10:42 AM EST - Fennec Pharmaceuticals Inc. : Today announced that the Tampa General Hospital Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection (PEDMARK®) in reducing the risk of ototoxicity in Adolescent and Young Adult (AYA) and adult cancer patients receiving cisplatin-based treatment. Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $10.95.
